Key Highlights:
- Foldax announced the commercial launch of the TRIA Mitral Valve in India in collaboration with Dolphin Life Science. The launch marks the first time a polymer heart valve has become commercially available to patients globally following approval from the Central Drugs Standard Control Organization.
- The TRIA Mitral Valve is designed to address key limitations of conventional valves. Unlike tissue valves that can calcify and degrade over time, or mechanical valves that require lifelong anticoagulation therapy, the polymer-based design aims to provide improved durability while supporting better long-term patient quality of life.
- To support adoption, Foldax has introduced the Evolve Training and Certification Program to train and certify physicians for implantation procedures. While the valve is approved for commercial use in India, it currently remains limited to investigational use in the US.
Implications:
TRIA disrupts India’s heart valve market by eliminating lifelong blood thinners, handing cardiothoracic surgeons a patient-friendly alternative to traditional choices.
Dolphin’s local manufacturing accelerates adoption across premium cardiac centers while positioning India as polymer valve innovation launchpad.
Valve breakthrough challenges tissue/mechanical duopoly, accelerating shift toward next-generation materials in high-volume mitral replacement surgeries.
Sources: Businesswire
No Comment! Be the first one.